by Raynovich Rod | Jan 17, 2023 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Biotech Stocks Rally During #JPM23 Favors Smaller Caps Bolt-On acquisitions expected to bolster product pipelines. Macro headwinds lessened with moderating inflation. Small and mid-cap biotechs provide an innovation narrative. Here are some takeaways from #JPM23:...
by Raynovich Rod | Apr 4, 2022 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-2 …4/6 In volatile end of day trading with Tech stocks and the NASDAQ hit hard down 2.2%, healthcare stocks were winners with the XLV up 1.5%. Other sector winners were staples, energy, real estate and utilities. As one pundit put it, ” the FED is...
by Raynovich Rod | Jan 16, 2021 | Biopharmaceuticals, vaccines
J.P. Morgan Healthcare Conference On a Rally Week-COVID Vaccines based on mRNA Platform COVID Vaccine availability drives the market and the global economy. The Vaccine market is huge with a long term need because of more viruses. The U.S COVID vaccine rollout is a...
by Raynovich Rod | May 18, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools, vaccines
Race to Develop a Coronavirus Vaccine Has $BB Funding with Several Major Players Update-3 5/20…Reversal to upside from yesterday’s sell-off. However the cynics are starting to come out questioning the timelines of some of the major COVID vaccine players...
by Raynovich Rod | Apr 4, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Coronavirus (COVID-19) is an infectious disease currently spreading across the globe. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover. Others (particularly elderly people and those with underlying medical...
by Raynovich Rod | Dec 13, 2018 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Update-2 After close: Market Collapses After FED Meeting-Bear Market WE all knew that the biotech sector likes looser monetary policy but this sell-off is ridiculous. The IBB is now at May 2017 levels! XBI breaks through 2018 technicals down 3.33% on downside to...